Showing results (1-10 of 229) with videos related to
Sort By:
Pageof 23
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 18, 2025
NLRP3 promoter methylation as a predictive biomarker for glucocorticoid response in patients with inflammatory bowel diseaseGiulia Zudeh, Davide Selvestrel, Matteo Bramuzzo, et al.Pharmacogenomics|September 1, 2004
Pharmacogenomics and stomach cancerGiuseppe Toffoli, Erika CecchinI Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|August 14, 2003
Pharmacogenetics of stomach cancerGiuseppe Toffoli, Erika CecchinPharmacogenomics|May 1, 2007
Pharmacogenetics and stomach cancer: an updateGiuseppe Toffoli, Erika CecchinGenes|April 17, 2019
Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 VariantsMarianna Lucafò, Gabriele Stocco, Stefano Martelossi, et al.International Journal of Molecular Sciences|August 23, 2020
Pharmacogenomics of AntibioticsGabriele Stocco, Marianna Lucafò, Giuliana DecortiWorld Journal of Gastroenterology|October 11, 2021
Induced pluripotent stem cells as an innovative model to study drug induced pancreatitisElena Genova, Gabriele Stocco, Giuliana DecortiCancer Chemotherapy and Pharmacology|August 11, 2020
miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathwayMarianna Lucafò, Daria Sicari, Andrea Chicco, et al.Expert Opinion on Drug Metabolism & Toxicology|January 21, 2016
Nuclear receptors and drug metabolism for the personalization of cancer therapyErika Cecchin, Elena De Mattia, Giuseppe ToffoliPageof 23